TP53 is one of the most frequently mutated genes in AML and is associated with a more aggressive form of the disease, treatment resistance, increased risk of relapse, and poor prognosis; hence, studying and enriching this pathway may help identify biomarkers that can be used as potential therapeutic targets. Here, TP53 is linked to acute myeloid leukemia.